West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. Asian Pacific Journal of Cancer Prevention 1513-7368 20 6 2019 06 01 Association between IL-18 -607 C/A Polymorphism and the Risk of Prostate Cancer: A Meta-Analysis of Case-Control Studies 1595 1602 88622 10.31557/APJCP.2019.20.6.1595 EN Gao Yuanyuan Department of Clinical Laboratory, First Affiliated Hospital of Soochow University, Suzhou, China. Central Laboratory of Pediatric Research Institute, Affiliated Children’s Hospital of Soochow University, Suzhou, China. Yu Xue Department of Clinical Laboratory, First Affiliated Hospital of Soochow University, Suzhou, China. Li Yachao Central Laboratory of Pediatric Research Institute, Affiliated Children’s Hospital of Soochow University, Suzhou, China. Feng Xiao Central Laboratory of Pediatric Research Institute, Affiliated Children’s Hospital of Soochow University, Suzhou, China. Chen Xu Department of Clinical Laboratory, First Affiliated Hospital of Soochow University, Suzhou, China. Journal Article 2018 07 15 Background: Accumulating evidence shows that cytokines play an important role in the proliferation of prostate<br />cancer. This research is trying to determine that IL-18 -607 C/A polymorphism confers susceptibility to prostate cancer.<br />Methods: Meta-analysis was used to collect data. The relevant studies were identified through a comprehensive search<br />from PubMed, Excerpta Medica Database (EMBASE), Web of Science, and Chinese Biomedical Literature Database<br />(CBM) to obtain related studies published up to December 6, 2017. The association between interleukin (IL)-18 -607 C/A<br />polymorphism and prostate cancer risk was assessed by odds ratios (ORs) together with their 95% confidence intervals<br />(CIs). Results: Nine case-control studies from 6 articles were eventually identified. In the overall population, there is a<br />significant association between IL-18 -607 C/A polymorphism and prostate cancer risk in recessive (CC versus CA/AA:<br />OR = 0.20, 95% CI = 0.15-0.27, P = 0.000) or dominant (CC/CA versus AA:OR = 0.42, 95% CI = 0.30–0.57, P = 0.000)<br />models. In the sub-group analysis according to ethnicity, for Asians, IL-18 -607 C/A polymorphism was significantly<br />associated with prostate cancer in allele contrast (C versus. A: OR=0.82, 95%CI=0.70-0.97, P=0.019), homozygote<br />(CC versus. AA: OR=0.68, 95%CI=0.50-0.92, P=0.013), recessive (CC versus. CA/AA: OR=0.19, 95%CI=0.13-0.27,<br />P=0.000), and dominant (CC/CA versus. AA: OR=0.37, 95%CI=0.28-0.48, P=0.000) models, for Caucasians, IL-18<br />-607 C/A polymorphism was significantly associated with prostate cancer risk in allele contrast (C versus. A: OR=1.27,<br />95%CI=1.02-1.58, P=0.033), homozygote (CC versus. AA: OR=1.86, 95%CI=1.19-2.91, P=0.007) and recessive (CC<br />versus. CA/AA: OR=0.25, 95%CI=0.19-0.33, P=0.000) models. Conclusion: This meta-analysis has shown that IL-18<br />-607 C/A polymorphism contributes to a decreased risk of prostate cancer risk in the Asian population but an increased<br />risk in the Caucasian population. https://journal.waocp.org/article_88622_c04fd00b2ba4cf91c7f1d29b8a4b7fa2.pdf